[LDL-cholesterol homogeneous assays versus Friedewald's equation]

Area of Science:

• Cardiovascular Medicine
• Clinical Chemistry

Background:

• Low-density lipoprotein (LDL) is a key risk factor for coronary artery disease and ischemic stroke.
• Clinical LDL-cholesterol (LDL-C) measurement relies on Friedewald's equation or homogeneous assays.
• Friedewald's equation, despite limitations, has been standard for ~40 years.

Purpose of the Study:

• To evaluate the current landscape of LDL-C measurement methods.
• To address the debate on the superiority of different LDL-C assays for clinical samples.

Main Methods:

• Review of widely used LDL-C calculation (Friedewald's equation) and homogeneous assay principles.
• Analysis of the availability and diversity of 12 homogeneous LDL-C assays in Japan.
• Consideration of undisclosed measurement principles for commercial assays.

Main Results:

• Friedewald's equation has limitations but remains prevalent.
• Multiple homogeneous LDL-C assays exist, utilizing different, undisclosed principles.
• The optimal method for clinical LDL-C measurement is debated.

Conclusions:

• The variety of LDL-C assays necessitates careful consideration for clinical application.
• Further research is needed to clarify the performance of different LDL-C assays.
• Standardization or clear guidelines may be required for accurate cardiovascular risk assessment.